Please login to the form below
Rapidscan/GE Healthcare distribution deal
Rapidscan choses GE Healthcare to distribute coronary artery disease treatment in the UK and Germany
Rapidscan Pharma Solutions EU (RPS) has come to an agreement with GE Healthcare to promote and distribute Rapiscan (regadenoson) in the UK and Germany.
Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease (CAD).
Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication.
Stephen Lightfoot, global MI-SPECT segment leader, Medical Diagnostics, GE Healthcare, said: "The opportunity to launch Rapiscan with Rapidscan Pharma Solutions EU leverages the expertise and unique capabilities of both organisations - to bring an important product used for the diagnosis of coronary artery disease to the UK and German marketplace."
Share
Related Hub content
Featured jobs
-
Associate Director
-
£75, 000-90, 000
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Account Director
-
Competitive Salary Offered
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Systematic Reviewer - Oxford
-
Negotiable
- Business Development Director – Health Education
-
excellent commission
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager
-
Negotiable
-
Medical (Scientific) Director
-
£120, 000 benefits
- Account Manager- Healthcare Advertising
-
Negotiable
- Account Manager- Healthcare Advertising
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Business Director
-
Competitive Salary Offered
- Principal Health Economist - North-West
-
Negotiable
-
Experienced Medical Writers
-
Competitive Salary and Benefits
Subscribe to our email news alerts
- Beneluxa: the future of European market access?
- Fishawack acquires Blue Latitude Health
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
- As May delays, industry warns again of ‘no-deal’ Brexit
- Clark Health Communications and Egg digital announce new collaboration
- Axovant drops last ‘legacy’ drug to focus on gene therapies
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
